Publications by authors named "C Hulin"
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort.
Clin Lymphoma Myeloma Leuk
September 2024
Introduction: Multiple myeloma patients aged 80 years and older are a population more prone to comorbidities and frailty. We aim to describe the real-life management and outcomes of this population. EMMY is a descriptive large-scale study.
View Article and Find Full Text PDFArticle Synopsis
- - The PERSEUS study analyzed the effects of adding daratumumab (D) to the standard treatment VRd (bortezomib, lenalidomide, and dexamethasone) for adults with newly diagnosed multiple myeloma to see if it could improve outcomes.
- - Participants were divided into two groups: one receiving D-VRd initially followed by D-R maintenance, and the other receiving standard VRd followed by lenalidomide alone.
- - After about four years, results indicated that those who received D-VRd had better treatment responses and were more likely to remain alive and disease-free compared to the VRd-only group, with side effects being consistent with expectations for both treatments.